Viewing Study NCT05268666

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:42 PM
Ignite Modification Date: 2026-01-05 @ 3:25 AM
Study NCT ID: NCT05268666
Status: UNKNOWN
Last Update Posted: 2023-06-15
First Post: 2022-02-11
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Sponsor: Jubilant Therapeutics Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Locally Advanced Solid Tumor View
None Metastatic Solid Tumor View
Keywords:

Keywords

Keyword Brief Keyword Text View
None SCLC View
None neuroendocrine prostate cancer View
None neuroendocrine View
None JBI-802 View